SecurityHCM / Hutchison China MediTech Limited (44842L103)
Institutional Owners39
Institutional Shares52,844,647
Institutional Value$ 883,332,000 USD
Related HNCMF / Hutchison China Meditech Ltd.

Institutional Stock Ownership and Shareholders

HCM / Hutchison China MediTech Limited Institutional Ownership

Hutchison China MediTech Limited (NASDAQ:HCM) has 39 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 52,844,647 shares. Largest shareholders include CK Hutchison Holdings Ltd, Prudential Plc, Mitsui & Co Ltd, Karst Peak Capital Ltd, Oppenheimer Funds Inc, JP Morgan Chase & Co, Schroder Investment Management Group, Wellington Management Group LLP, Bellevue Group AG, and Allianz Asset Management AG.
Hutchison China MediTech Limited (NASDAQ:HCM) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/hcm"><img src="https://images.fintel.io/us-hcm-so.png" alt="HCM / Hutchison China MediTech Limited Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR INDUS CAPITAL PARTNERS, LLC 24,800 24,800 0.00 978 733 -25.05
2018-05-15 13F-HR PIONEER INVESTMENT MANAGEMENT INC 51,999 54,599 5.00 2,049 1,614 -21.23
2018-05-08 13F-HR Bt Investment Management Ltd 16,936 500,628
2018-05-11 13F-HR CITADEL ADVISORS LLC 9,674 286
2018-05-10 13F-HR JP Morgan Chase & Co 1,253,084 1,527,742 21.92 49,397 45,159 -8.58
2018-05-15 13F-HR AQR CAPITAL MANAGEMENT LLC 15,005 48,809 225.28 591 1,443 144.16
2018-05-09 13F-HR Bellevue Group AG 133,850 302,420 125.94 5,258 8,940 70.03
2018-05-14 13F-HR Prince Street Capital Management LLC 61,300 81,400 32.79 2,416 2,406 -0.41
2018-05-04 13F-HR MCKINLEY CAPITAL MANAGEMENT LLC /DELAWARE 31,399 24,238 -22.81 1,237 717 -42.04
2018-05-15 13F-HR Polar Capital LLP 30,000 0 -100.00 1,154 0 -100.00
2018-05-03 13F-HR DekaBank Deutsche Girozentrale 30,000 866
2018-05-11 13F-HR GSA CAPITAL PARTNERS LLP 90,600 201,268 122.15 3,571 5,949 66.59
2018-05-01 13F-HR COMERICA BANK 6,519 6,599 1.23 246 222 -9.76
2018-05-11 13F-HR OPPENHEIMER FUNDS INC 1,691,980 1,684,770 -0.43 66,697 49,802 -25.33
2017-02-13 SC 13G MITSUI & CO LTD 3,214,404
2018-05-14 13F-HR MORGAN STANLEY 132 11,329 8,482.58 5 334 6,580.00
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 0 34,129 0 1,009
2018-05-15 13F-HR Jabre Capital Partners S.A. 34,058 39,087 14.77 1,343 1,155 -14.00
2018-05-14 13F-HR Renaissance Technologies LLC 69,800 149,800 114.61 2,752 4,428 60.90
2018-05-15 13F-HR Wellington Management Group LLP 517,255 580,527 12.23 20,390 17,161 -15.84
2017-02-08 SC 13G CK Hutchison Holdings Ltd 36,666,667
2018-05-15 13F-HR Folger Hill Asset Management LP 60,342 42,772 -29.12 2,379 1,264 -46.87
2018-05-15 13F-HR Advisor Group, Inc. 454 352 -22.47 18 10 -44.44
2018-05-15 13F-HR PRUDENTIAL PLC 2,190,838 3,897,456 77.90 86,363 115,209 33.40
2018-05-23 13F-HR/A Allianz Asset Management AG 175,300 237,973 35.75 6,910 7,034 1.79
2018-05-08 13F-HR Harvest Fund Management Co., Ltd 262,160 164,184 -37.37 10,334 4,852 -53.05
2018-05-14 13F-HR CASTLEARK MANAGEMENT LLC 4,500 4,500 0.00 177 133 -24.86
2018-05-10 13F-HR MATTHEWS INTERNATIONAL CAPITAL MANAGEMENT LLC 254,300 0 -100.00 10,025 0 -100.00
2018-04-23 13F-HR World Asset Management Inc 6,873 0 -100.00 271 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 33,965 27,087 -20.25 1,340 801 -40.22
2018-05-15 13F-HR UBS Group AG 2,025 2,612 28.99 80 78 -2.50
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 0 200 0 6
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 1,158 3,594 210.36 45 106 135.56
2018-05-11 13F-HR/A SCHRODER INVESTMENT MANAGEMENT GROUP 1,154,164 1,281,443 11.03 45,497 37,879 -16.74
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 6,747 199
2018-05-01 13F-HR Sumitomo Mitsui Trust Holdings, Inc. 108,085 108,085 0.00 4,261 3,195 -25.02
2018-05-15 13F-HR PERCEPTIVE ADVISORS LLC 10,000 10,000 0.00 394 296 -24.87
2018-05-15 13F-HR Karst Peak Capital Ltd 1,205,580 2,005,580 66.36 47,524 59,285 24.75
2018-05-10 13F-HR BAILLIE GIFFORD & CO 206,454 206,140 -0.15 8,138 6,093 -25.13
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 6,554 0 -100.00 258 0 -100.00
2018-05-14 13F-HR Hudson Bay Capital Management LP 17,200 17,200 0.00 678 508 -25.07
2018-05-15 13F-HR DEUTSCHE BANK AG\ 29,785 64,233 115.66 1,174 1,898 61.67
2018-05-11 13F-HR HSBC HOLDINGS PLC 64,753 0 -100.00 2,553 0 -100.00
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 103,799 45,617 -56.05 4,092 1,348 -67.06
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 9,674 286

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

20h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

2018-06-07 seekingalpha
Novocure strengthened its Board of Directors and Abeona Therapeutics received a key analyst thumbs up. Two possible trades are suggested. (627-6)

China weighs new high-tech stock venue in battle with Hong Kong, people say

2018-06-05 scmp
China is expanding efforts to keep its most promising companies from going public in Hong Kong or the US, with officials studying a new trading venue in Shanghai that would have lower thresholds for biotechnology and high-tech firms, people with knowledge of the matter said. (86-0)

Gama shareholders urged not to re-elect director

2018-06-02 telegraph.co.uk
A shareholder advisory group is urging investors to vote against the re-election of Gama Aviation director Simon To, citing “independence issues” with his position on the board’s remuneration committee. (3-0)

Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap

2018-05-31 seekingalpha
FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme. (666-4)

CK Hutchison: 60% Upside Potential

2018-05-28 seekingalpha
CK Hutchison is an empire with infrastructure, telecom and energy businesses, which produces growing cash flow over time. (1-1)

CUSIP: 44842L103